Imaging characteristics of young age breast cancer (YABC) focusing on pathologic correlation and disease recurrence

Jeongmin Lee¹, Sung Hun Kim³, Bong Joo Kang¹, Ahwon Lee², Woo-Chan Park³ & Jinwoo Hwang⁴

The purpose of this study is to investigate imaging characteristics of young age breast cancer (YABC) focusing on correlation with pathologic factors and association with disease recurrence. From January 2017 to December 2019, patients under 40 years old who were diagnosed as breast cancer were enrolled in this study. Morphologic analysis of tumor and multiple quantitative parameters were obtained from pre-treatment dynamic contrast enhanced breast magnetic resonance imaging (DCE-MRI). Tumor-stroma ratio (TSR), microvessel density (MVD) and endothelial Notch 1 (EC Notch 1) were investigated for correlation with imaging parameters. In addition, recurrence associated factors were assessed using both clinico-pathologic factors and imaging parameters. A total of 53 patients were enrolled. Several imaging parameters derived from apparent diffusion coefficient (ADC) histogram showed negative correlation with TSR; and there was negative correlation between MVD and Ve in perfusion analysis. There were nine cases of recurrences with median interval of 16 months. Triple negative subtype and low CD34 MVD positivity in Notch 1 hotspots showed significant association with tumor recurrence. Texture parameters reflecting tumor sphericity and homogeneity were also associated with disease recurrence. In conclusion, several quantitative MRI parameters can be used as imaging biomarkers for tumor microenvironment and can predict disease recurrence in YABC.

Breast cancer has become one of the leading causes of death in Asian women and its incidence in Asia has been increasing steadily¹-⁴. Along with this trend, the different epidemiology of Asian breast cancer is now being focused on. Especially, its peak age is one of the biggest differences with breast cancer of the West. Its peak age is in the 70 s in the West, whilst it is in the late 40 s in the East. Moreover, the proportion of premenopausal women is higher compared to the West. Despite the higher incidence in the West, the proportion of breast cancer in young women under 40 s and premenopausal women is higher in the East than in the West⁵-⁸.

These epidemiologic differences could affect the treatment of breast cancer. However, the treatment guidelines are mostly based on the characteristics of breast cancer of the West, which are focused on post-menopausal women. Recently, several clinical studies have been conducted to find proper treatment for Asian young age breast cancer (YABC) and some have shown significant results such as additional Ribociclib therapy to traditional endocrine therapy⁹,¹⁰. Treatments or screening guidelines based on these differences are needed for Asian women. For example, in Asian breast cancer, menopausal status should be considered in treatment and a more personalized consideration is needed for patients of childbearing age⁵,⁶.

Since young age is known as an independent risk factor for recurrence in breast cancer¹¹,¹², it is important to accurately evaluate the disease status when planning treatment for YABC. However, biopsy tissue often reflects only a portion of the tumor due to its heterogeneity. Imaging features or parameters on breast magnetic resonance imaging (MRI), unlike biopsy, are more accessible than pathologic characteristics and can noninvasively and comprehensively provide information of the entire tumor. However, there have been only a few studies on imaging characteristics of YABC.

¹Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea. ²Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. ³Division of Breast-Thyroid Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. ⁴Philips Healthcare Korea, Seoul, Republic of Korea. ⁵Email: rad-ksh@catholic.ac.kr
Based on this background, we tried to assess how imaging parameters reflect pathologic features through MRI. Also, we investigated the imaging features associated with breast cancer recurrence in YABC.

**Result**

**Patients.** Sixty patients agreed and were enrolled in this study. Of the 60 patients, three withdrew their consent to participate in other clinical trials before MRI acquisition, and four withdrew their consent after MRI acquisition. Finally, 53 patients were enrolled. The median age of patients was 36 (range 23–39) years old and median period of follow up after surgery was 21.5 months (range 10–33). Of the finally enrolled 53 patients, 12 patients underwent neoadjuvant chemotherapy before surgery and 22 patients underwent adjuvant chemotherapy. Thirty-eight patients underwent breast conserving surgery followed by adjuvant radiation therapy. There were 51 cases of invasive ductal carcinoma and 2 cases of mucinous carcinoma. Based on pathologic report after surgery, stage 1A was the most common (n = 23) disease stage and luminal type was the most common tumor subtype by immunohistochemistry (n = 32). Eight patients underwent neoadjuvant chemotherapy and achieved complete remission before surgery. These patients were confirmed as stage 0 on pathology after surgery. At a median follow up of 21.5 months, there were 9 cases of recurrence. Five cases recurred at ipsilateral breast and one case recurred at contralateral breast. One case recurred as an ipsilateral axillary metastasis and two cases recurred as distant metastasis. Apart from these nine recurrent cases, there was one case with endometrial cancer as a second primary cancer. Recurrent cases were identified within average of 13.8 months (median 16 months, range 1–31 months) after surgery. Among the nine recurrent cases, 5 were triple negative subtypes (Fig. 1). Other details of patient characteristics are described in Table 1.

**Correlation between pathologic factors and imaging parameters.** Apparent diffusion coefficient histogram and tumor-stroma ratio. Of the 52 patients who performed tumor-stroma ratio (TSR) analysis, 43 patients were stroma-poor type and 9 were stroma-rich type. Mean apparent diffusion coefficient (ADC) value of stroma-poor type was significantly lower than that of stroma-rich type ($p = 0.006$) (Table 2). Negative correlation was revealed among TSR and several parameters of ADC histogram: minimum value, mean value, median value, 5th percentile, 10th percentile, 25th percentile, 75th percentile and 90th percentile (Table 3).

**Perfusion parameters and endothelial notch 1 and microvessel density.** The endothelial Notch 1 (EC notch 1) and microvessel density (MVD) analyses were performed in 45 patients of 53 patients. There was no association between perfusion parameters and EC notch 1. Of the multiple parameters from perfusion analysis, only the mean value of Ve showed negative correlation with MVD (correlation coefficient = $-0.30, p < 0.046$).
|                          | Total (n = 53) | Non-recurrence group (n = 44) | Recurrence group (n = 9) | p value |
|--------------------------|---------------|------------------------------|-------------------------|---------|
| Age (median)             | 36            | 36                           | 35                      | 1       |
| **Operation type**       |               |                              |                         |         |
| Breast conserving surgery| 38 (74.5)     | 31 (73.8)                    | 7 (77.8)                |         |
| Mastectomy               | 13 (25.5)     | 11 (26.2)                    | 2 (22.2)                |         |
| **BRCA mutation**        |               |                              |                         | 1       |
| Negative                 | 14 (63.6)     | 11 (64.7)                    | 3 (60)                  |         |
| Positive                 | 8 (36.4)      | 6 (35.3)                     | 2 (40)                  |         |
| **Radiation therapy**    |               |                              |                         | 1       |
| Yes                      | 46 (88.5)     | 38 (88.4)                    | 8 (88.9)                | 0.185   |
| No                       | 6 (11.5)      | 5 (11.6)                     | 1 (11.1)                |         |
| **Neoadjuvant chemotherapy** |            |                              |                         |         |
| Yes                      | 12 (23.1)     | 8 (18.6)                     | 4 (44.4)                | 0.144   |
| No                       | 40 (76.9)     | 35 (81.4)                    | 5 (55.6)                |         |
| **Adjuvant chemotherapy**|              |                              |                         |         |
| Yes                      | 22 (42.3)     | 16 (37.2)                    | 6 (66.7)                | 0.33    |
| No                       | 30 (57.7)     | 27 (62.8)                    | 3 (33.3)                |         |
| **Target therapy (Herceptin)** |        |                              |                         |         |
| Yes                      | 9 (17.3)      | 9 (20.9)                     | 0 (0)                   | 0.024   |
| No                       | 43 (82.7)     | 34 (79.1)                    | 9 (100)                 |         |
| **Adjuvant hormone therapy** |           |                              |                         |         |
| Yes                      | 39 (76.5)     | 35 (83.3)                    | 4 (44.4)                | 0.366   |
| No                       | 12 (23.5)     | 7 (16.7)                     | 5 (55.6)                |         |
| **Pathologic staging†**  |              |                              |                         | 0.313   |
| Stage 0                  | 4 (7.7)       | 4 (9.3)                      | 0 (0)                   |         |
| Stage I (1a, 1b)         | 24 (46.2)     | 21 (48.8)                    | 3 (33.3)                |         |
| Stage II (2a, 2b)        | 22 (42.3)     | 16 (37.2)                    | 6 (66.7)                |         |
| Stage III (3a)           | 2 (3.8)       | 2 (4.7)                      | 0 (0)                   |         |
| **Histologic type**      |               |                              |                         | 0.364   |
| Invasive breast cancer, NST | 51 (96.2)   | 43 (97.7)                    | 8 (88.9)                |         |
| Invasive lobular carcinoma|               |                              |                         |         |
| Mucinous carcinoma       | 2 (3.8)       | 1 (2.3)                      | 1 (11.1)                |         |
| **Histologic grade††**   |              |                              |                         | 0.02    |
| Grade 1                  | 11 (20.8)     | 10 (22.7)                    | 1 (11.1)                |         |
| Grade 2                  | 18 (34)       | 16 (36.4)                    | 2 (22.2)                |         |
| Grade 3                  | 24 (45.3)     | 18 (40.9)                    | 6 (66.7)                |         |
| **Estrogen receptor**    |              |                              |                         | 0.044   |
| Positive                 | 41 (77.4)     | 37 (84.1)                    | 4 (44.4)                |         |
| Negative                 | 12 (22.6)     | 7 (15.9)                     | 5 (55.6)                |         |
| **Progestosterone receptor** |           |                              |                         | 0.175   |
| Positive                 | 39 (73.6)     | 35 (79.5)                    | 4 (44.4)                |         |
| Negative                 | 14 (26.4)     | 9 (20.5)                     | 5 (55.6)                |         |
| **HER2**                 |              |                              |                         | 0.056   |
| Positive                 | 8 (18.2)      | 8 (22.9)                     | 0 (0)                   |         |
| Negative                 | 36 (81.8)     | 27 (77.1)                    | 9 (100)                 |         |
| Ki 67 (%)                | 41.9 ± 28.6   | 37 ± 25.6                    | 57.6 ± 32.7             |         |
| **Subtype**              |              |                              |                         | 0.006   |
| Luminal                  | 32 (61.5)     | 28 (65.1)                    | 4 (44.4)                |         |
| HER2                     | 10 (19.2)     | 10 (23.3)                    | 0 (0)                   |         |
| Triple negative          | 10 (19.2)     | 5 (11.6)                     | 5 (55.6)                |         |
| **Tumor stromal ratio (TSR)** |       |                              |                         | 0.645   |
| Stromal predominant      | 9 (17.3)      | 7 (16.3)                     | 2 (22.2)                |         |
| Tumor predominant        | 43 (82.7)     | 36 (83.7)                    | 7 (77.8)                |         |
| **Stromal type**         |              |                              |                         | 0.579   |
| Collagen                 | 12 (24)       | 10 (24.4)                    | 2 (22.2)                |         |
| Fibroblast               | 32 (64)       | 27 (63.9)                    | 5 (55.6)                |         |
| Lymphocyte               | 6 (12)        | 4 (9.8)                      | 2 (22.2)                |         |
| Continued                |              |                              |                         |         |
Recurrence associated factors. Clinico-pathologic factors. There were 9 cases of tumor recurrence including loco-regional recurrence and distant metastases. The recurrence group showed significantly higher estrogen receptor (ER) negativity and progesterone (PR) negativity ($p = 0.02, 0.044$) than in non-recurrence group; and Ki-67 index tended to be higher in recurrence group ($57.6 \pm 32.7$ [SD], $p = 0.056$). Lack of adjuvant hormone therapy was also higher in recurrence group ($p = 0.024$). The ER negativity, PR negativity and lack of adjuvant hormone therapy also showed significantly increased risk for disease recurrence (Table 4). Ten cases of the total 53 cases were triple negative subtypes. Of these 10 cases, 5 cases had disease recurrence accounting for 55.6%

| Central necrosis | Total (n = 53) | Non-recurrence group (n = 44) | Recurrence group (n = 9) | $p$ value |
|------------------|---------------|------------------------------|-------------------------|-----------|
| Absent           | 47 (94)       | 39 (95.1)                    | 8 (88.9)                | 0.456     |
| Present          | 3 (6)         | 2 (4.9)                      | 1 (11.1)                |           |
| Tumor infiltration lymphocyte (TIL) | | | | |
| Low (< 50%)      | 43 (86)       | 36 (87.8)                    | 7 (77.8)                |           |
| High (≥ 50%)     | 7 (14)        | 5 (12.2)                     | 2 (22.2)                |           |
| Notch 1          | 9.7 ± 5.5     | 9.5 ± 5.3                    | 11 ± 6.9                | 0.529     |
| Notch1-DC        | 102.8 ± 28.9  | 105.7 ± 26.9                 | 86.6 ± 36.4             | 0.042     |
| EC Notch 1       | 0.11 ± 0.05   | 0.09 ± 0.05                  | 0.12 ± 0.05             | 0.094     |
| microvessel density (MVD) | 114.1 ± 28.9 | 115.7 ± 28.6 | 105.2 ± 31.3 | 0.383     |
| Notch tumor H score | 16 ± 25.8 | 14.31 ± 25.1 | 25.7 ± 29.5 | 0.093     |

Table 1. Clinico-pathologic characteristic of patients. † Based on AJCC 7th, including yp stage. †† Nottingham histologic grade.

| Pathologic parameters | Mean ADC values (SD) ($\times 10^{-3}$ mm$^2$/s) | $p$ value |
|-----------------------|-------------------------------------------------|-----------|
| Tumor-stroma ratio    |                                                |           |
| Stroma-poor (n = 43)  | 0.991 ± 0.053                                   | 0.006     |
| Stroma-rich (n = 9)   | 1.391 ± 0.172                                   |           |
| Stroma type           |                                                | 0.561     |
| Collagenous (n = 12)  | 1.120 ± 0.143                                   |           |
| Fibroblastic (n = 32) | 1.009 ± 0.057                                   |           |
| Lymphocytic (n = 6)   | 1.144 ± 0.153                                   |           |
| Central necrosis      |                                                |           |
| Absent (n = 47)       | 1.061 ± 0.056                                   | 0.622     |
| Present (n = 3)       | 0.946 ± 0.046                                   |           |
| Tumor-lymphocytic infiltration 50% | | | | |
| Low (n = 43)          | 1.049 ± 0.058                                   | 0.79      |
| High (n = 7)          | 1.087 ± 0.144                                   |           |

Table 2. Mean ADC† values according to pathologic parameters. † Apparent diffusion coefficient.

| ADC histogram | Correlation coefficient | $p$ value |
|---------------|-------------------------|-----------|
| Minimum       | − 0.4599                | 0.001     |
| Maximum       | − 0.1141                | 0.421     |
| Mean          | − 0.3467                | 0.018     |
| Skewness      | 0.0935                  | 0.021     |
| Kurtosis      | − 0.1153                | 0.51      |
| 5th percentile | − 0.3997               | 0.416     |
| 10th percentile| − 0.3916               | 0.003     |
| 25th percentile| − 0.3755               | 0.004     |
| 75th percentile| − 0.3159               | 0.006     |
| 90th percentile| − 0.2911               | 0.023     |
| 95th percentile| − 0.2694               | 0.036     |

Table 3. Correlation coefficient between ADC† values and tumor-stroma ratio. † Apparent diffusion coefficient.
In addition, triple negative subtype showed the highest risk of disease recurrence among clinical-pathological factors (OR 9.75, 95% CI 1.95–48.83, p = 0.019).

In immunohistochemical staining, lower positivity of CD34 MVD in Notch1 hot spots was significantly associated with disease recurrence (OR 9.00, 95% CI 1.34–60.46, p = 0.020).

Table 4. Disease-recurrence associated clinico-pathologic factors.

| Factors                        | Odds ratio (95% CI) | p value |
|-------------------------------|---------------------|---------|
| Estrogen receptor negativity  | 6.61 (1.41–30.92)   | 0.016   |
| Progesterone receptor negativity| 4.86 (1.08–21.90)  | 0.039   |
| Lack of adjuvant hormone therapy| 6.25 (1.33–29.30)  | 0.020   |
| Triple negative subtype       | 7.00 (1.38–35.83)   | 0.019   |
| Notch1-CD34MVD (< 72.6)       | 9.00 (1.34–60.46)   | 0.020   |

Figure 2. Low positive CD34 MVD in recurrent breast cancer. Immunohistochemical staining of Notch1 (a) and CD34 (b) at Notch 1 hotspots (original magnification ×200). Red arrow heads indicate Notch 1 positive microvessels (a), and some of CD34 positive microvessels are noted (b) among Notch 1 positive microvessels. In the same patient, (c) shows high level of CD34 MVD (brown colored) measurement in the entire tissue. However, the positivity of CD34 MVD in Notch 1 hotspots was as low as shown in (b). The patient was diagnosed as recurrent breast cancer 3 months after surgery.
Imaging factors.

1. Qualitative parameters: morphologic characteristics

The mean size of the tumor was 2.9 cm (mean 2.88 cm ± 2.05 [SD]). In the recurrence group, the mean size of tumor was 3.9 cm (3.9 cm ± 1.7 [SD]), which was significantly larger than that of the tumor in non-recurrence group (mean 2.7 cm ± 2.1 [SD], p = 0.02). However, the increase in the mean size of tumors was not significantly associated with disease recurrence (p = 0.081).

More than half of the mass cases manifested as oval shape (n = 27, 57.5%) with circumscribed margin (n = 26, 55.3%). Except for one case of mucinous carcinoma which lacked enhancement, all mass lesions showed heterogeneous or rim enhancement. However, these morphologic features showed no significant difference between recurrence and non-recurrence group.

The peritumoral edema was found only in 14 cases (26.4%). It was more frequently found in the recurrence group (55.6%, p = 0.044), and it was a significant factor for disease recurrence (OR 4.861, 95% CI 1.08–21.90, p = 0.039).

Mass shape, distribution of non-mass enhancement, number of prominent vessels around the index cancer, and other non-tumor factors showed no significant association with disease recurrence. The difference in whole qualitative parameters including morphologic characteristics of tumor and non-tumor factors between recurrence and non-recurrence groups is provided as Supplementary Table 1.

2. Quantitative parameters

From texture analysis, multiple parameters showed significant difference between recurrence and non-recurrence group (Supplementary Table 2). Among these parameters, low surface area to volume ratio calculated from T2-weighted imaging (T2WI) (OR 15.625, 95% CI 2.94–82.84, p = 0.001) and ADC map (OR 16.949, 95% CI 2.93–99.44, p = 0.002) showed the highest risk increase from other parameters. Of the first order features, only parameters calculated on the ADC map were correlated with disease recurrence; however, features such as entropy, kurtosis or skewness, which are commonly referred to describe tumor texture features, were not included. Of the second-order features, one gray level co-occurrence matrix (GLCM) feature calculated on the ADC map showed increased risk for the disease recurrence: inverse difference moment (IDM) (OR 5.625, 95% CI 1.23–25.76, p = 0.026), which is a measure of local homogeneity. In similar context, lower value of run length non uniformity normalized feature, a kind of homogeneity in image, showed the tendency to increase the risk of disease recurrence (OR 8.00, 95% CI 1.08–21.90, p = 0.059) (Table 5).

There was no significant association between perfusion parameters, and ADC histogram and recurrence in our study.

Discussion

In this study, imaging characteristics of YABC were assessed focusing on their correlation with pathologic factors and on association with disease recurrence.

In the correlation between pathological factors and imaging parameters, TSR and ADC value, and MVD and Ve value showed correlation with each other. These were consistent with previous studies[14–15]. However, these pathologic factors and imaging parameters showed no significant correlation with disease recurrence in our study. The association between TSR and disease recurrence showed results that contradict the previous studies. In one previous study, stroma-rich type tumor showed higher relapse rate in triple negative breast cancer[16]. However, five cases of triple negative subtype with disease recurrence were all stroma-poor tumors in our study.

Although there was no significant association between EC Notch1 and image parameters, CD34 MVD in Notch1 hot spots showed negative correlation with disease recurrence. Despite that higher MVD showed association with poor prognosis of tumor in general, CD34 MVD showed contradictory result to previous studies[17]. This result may be due to the limitation of the small number of cases in our study. However, CD34 MVD in Notch1 hot spots may be a new prognostic factor with different means from CD34 MVD measured in the entire tumor tissue. Further research is needed in the future for validation of this result.

According to previous studies on imaging characteristics of YABC, breast cancer under 40 years of age showed irregular shape with irregular or spiculated margin and internal heterogeneous enhancement pattern on MRI[18–19]. These are typical findings of breast malignancy in average age women. However, more than half of the malignancies in our study manifested as mass lesions with oval shape with circumscribed margin, which is different from previous studies[20]. In addition, low value of surface area to volume ratio from T2WI and ADC map showed the highest correlation with recurrence on texture analysis. In other words, the more spherical the three-dimensional shape of the tumor is, the higher the association with recurrence. These morphologic features are similar to triple negative subtype breast cancer, which generally shows as mass with smooth or circumscribed margin[21–22]. Considering the high recurrence rate of triple negative subtype[23–24], the results are consistent with previous studies. Moreover, triple negative subtypes accounted for more than half of the recurrence group in our study. Our results are not only consistent with previous studies, but also are more meaningful because they have been more objectively verified through texture analysis.

High value of IDM from ADC map also showed correlation with disease recurrence. This result is not consistent with the results of previous studies because the IDM indicates homogeneity of the tumor. In a previous study, the ADC value difference of tumor could reflect tumor heterogeneity; and high ADC value difference was associated with distant metastasis in breast cancer patients with mean age of 50 years old[25]. In this previous study,
| Factors | Odds ratio (95% CI) | p value |
|--------|------------------|---------|
| **Quantitative** | | |
| Peritumoral edema positivity | 4.86 (1.08–21.90) | 0.039 |
| **Qualitative** | | |
| **Texture analysis: subtracted early phase of contrast enhanced fat saturated T1WI** | | |
| Original gray level run length matrix run length non uniformity normalized | | |
| ≥0.92 | 8.00 (0.92–69.45) | 0.059 |
| <0.92 | Reference | |
| **Texture analysis: T2WI** | | |
| Original shape surface area to volume ratio | | |
| <0.388 | 15.60 (2.9378–82.8381) | 0.001 |
| ≥0.388 | Reference | |
| Original gray level run length matrix long run low gray level emphasis | | |
| ≥0.00616 | 10.14 (0.92–69.45) | 0.059 |
| <0.00616 | Reference | |
| **Texture analysis: ADC map** | | |
| Original shape surface area to volume ratio | | |
| <0.31113 | 17.08 (2.9346–99.4468) | 0.002 |
| ≥0.31113 | Reference | |
| Original shape least axis | | |
| ≥17.429 | 6.000 | 0.023 |
| <17.429 | Reference | |
| Original first order energy | | |
| ≥604,233,589 | 5.559 | 0.046 |
| <604,233,589 | Reference | |
| Original first order total energy | | |
| ≥2,832,352,151 | 12.706 | 0.021 |
| <2,832,352,151 | Reference | |
| Original first order 10th percentile | | |
| ≥851 | 4.861 | 0.039 |
| <851 | Reference | |
| Original first order 90th percentile | | |
| ≥2243 | 7.778 | 0.010 |
| <2243 | Reference | |
| Original first order maximum | | |
| ≥2128 | 12.706 | 0.021 |
| <2128 | Reference | |
| Original first order median | | |
| ≥1516 | 7.778 | 0.010 |
| <1516 | Reference | |
| Original first order range | | |
| ≥2128 | 14.000 | 0.017 |
| <2128 | Reference | |
| Original first order mean absolute deviation | | |
| ≥403.389 | 6.800 | 0.016 |
| <403.389 | Reference | |
| Original first order root mean squared | | |
| ≥1653.109 | 7.778 | 0.010 |
| <1653.109 | Reference | |
| Original first order SD | | |
| ≥352.99 | 6.767 | 0.027 |
| <352.99 | Reference | |
| Original first order variance | | |
| ≥124,601.6 | 15.467 | 0.013 |
the ADC value difference was measured only on one section with the widest diameter of tumors. In our study, texture parameters of ADC map were measured in three dimensions to reflect the heterogeneity or homogeneity of the ADC value of the entire tumor. Another previous study has proven increased uniformity and decreased entropy in high histologic grade tumor\(^6\), though the texture parameters were measured on contrast-enhanced T1-weighted subtraction images.

These results, which are inconsistent with previous studies, may be the unique features of young age breast cancer because there are few studies on pathologic factors and quantitative MR parameters focusing on breast cancer in women under 40 years old.

Several texture parameters from ADC map showed significant correlation with disease recurrence whereas some previous studies showed that texture analysis of ADC map could not help predict the prognosis of breast cancer\(^7,8\). Diffusion weighted imaging (DWI) is emerging as a non-contrast imaging to replace contrast-enhanced MRI due to safety from gadolinium-based contrast agents. Thus, our results can be regarded as meaningful since many significant results were obtained from DWI. Based on this, DWI may have the potential to be a surveillance tool for high-risk young women who need annual contrast enhanced breast MRI by recommendation of American College of Radiology\(^9\).

There are few limitations in our study. Despite its prospective nature, this is a single center study; and the number of enrolled patients and event number are small, which could weaken the representatives of characteristics of YABC. In addition, the follow-up period after surgery was not enough, considering disease free survival of hormone receptor positive breast cancer. There were also some missing data in pathological factors and MR parameters.

Despite these limitations, this prospective study would have the novelty for description of imaging characteristics of YABC focusing on the correlation with pathologic factors and disease recurrence. Low CD34 MVD in Notch 1 hot spots and tumor homogeneity on ADC map, which showed correlation with disease recurrence, were contradictory to results of previous studies. These can be the unique features of YABC, although further validation would be needed with larger number of patients and longer follow-up period. In the situation where Asian breast cancer with a high proportion of young age women is rapidly increasing, studies to reveal the characteristics of YABC are necessary. Therefore, we expect this study to be the milestone of future studies that may reveal the characteristics of YABC.

**Materials and methods**

**Patients.** This prospective study was approved by institutional review board of Seoul St. Mary’s Hospital (reference number, KC16EISI0425) and assessments were carried out as per the rules of the Declaration of Helsinki of 1975, revised in 2013. From August 2017 to August 2019, patients diagnosed with invasive breast cancer under 40 years of age were the subjects for this study. Every patient was provided with informed consent before enrollment and agreed to undergo pre-treatment breast MRI with specific sequences in our institution for this study.

**MRI.** MRIs were performed for patients in prone position using a 3-Tesla MR scanner (Ingenia, Philips Medical Systems, Best, The Netherlands) and a dedicated eight-channel phase-array coil. Images were obtained using the following sequences: (1) axial turbo spin-echo T2WI with TR/TE of 3624/80 ms, flip angle of 90°, field of view (FOV) of 320×320 mm\(^2\), matrix size of 532×306, slice thickness of 2 mm, and acquisition time of 2 min 23 s; (2) pre-contrast T1-weighted High Resolution Isotropic Volume Examination (THRIVE) with TR/TE of 9.0/2.0 ms, FOV of 300×300 mm\(^2\), matrix size of 256×204, slice thickness of 2 mm, flip angle of 5°, 10° and 20°, and acquisition time of 2 min 45 s to determine tissue T1 relaxation time prior to the arrival of contrast agent; (3) dynamic contrast enhanced axial T1-weighted imaging (DCE-T1WI) with fat suppression with TR/TE of 9.0/2.0 ms, flip angle of 8°, slice thickness of 2.0 mm, and acquisition time of 5 min 30 s (temporal resolution 6 s) following an intravenous bolus injection of 0.1 mmol/kg gadobutol (Gadovist, Schering, Berlin, Germany) followed by a 20 ml saline flush; (4) delayed axial TRIVE with TR/TE of 4.5/2.0 ms, flip angle of 12°, slice thickness of 1.0 mm, FOV of 340×340 mm\(^2\), matrix size of 380×377 for evaluation of overall extent of tumor.

DWI was performed before dynamic contrast enhanced MRI, using a single-shot spin-echo EPI pulse sequence with TR/TE 12,043.5/102.3 ms, flip angle of 90°, FOV of 320×320 mm\(^2\), matrix size of 184×184, slice thickness of 3 mm, using three b values (b = 0, 1000 s/mm\(^2\)). The ADC map was calculated with mono-exponential fit using a b value of 1000.

| Factors                                      | Odds ratio (95% CI)   | p value |
|----------------------------------------------|----------------------|---------|
| Original gray level co-occurrence matrix inverse difference moment | Reference            |         |
| ≥0.155                                       | 5.62 (1.23–25.76)    | 0.026   |
| <0.155                                       | Reference            |         |

Table 5. Disease-recurrence associated imaging factors. †Weighted image. ††Apparent diffusion coefficient.
Clinical and pathologic information. Medical records of all enrolled patients were reviewed. Clinical information included patient’s age, date of surgery, the last date of outpatient clinic after surgery, date of disease recurrence, and the type of treatment received including surgery, chemotherapy, hormonal therapy and target therapy. Pathologic information of breast cancer included histologic type and grade, hormonal receptor status, human epidermal growth factor receptor 2 (HER2) status, Ki-67 index, and pathologic TNM staging by AJCC 7th.

Several additional pathologic analyses were performed including TSR, EC notch 1 and MVD of tumor. These factors were known as prognostic factors in previous studies and showed some correlation with imaging parameters: ADC values and perfusion parameters. EC Notch 1 has not been identified to correlate with imaging parameters to our knowledge. However, since this factor is already known as an angiogenesis-reflecting factor, we expect it to be able to predict the association with perfusion parameters; Ktrans, Kep and Ve.

These analyses were performed with surgical specimen. However, the tissue obtained from the core-needle biopsy at the time of cancer diagnosis was used if the patient underwent neoadjuvant chemotherapy. Staining of MVD and EC Notch 1 was omitted in cases of biopsy-tissue acquired in other hospitals.

Recurrence was defined as one of the followings: newly diagnosed breast cancer, axillary lymph node metastasis, or distant metastasis after surgery. Recurrent diseases were diagnosed by pathological confirmation when biopsy was possible; and in cases where biopsy was unavailable, other imaging modalities such as computed tomography (CT), or positron emission tomography (PET) -CT were used.

Ethical approval. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent. Informed consent was obtained from all individual participants included in the study.

Imaging analysis
Morphologic analysis. Two breast expert radiologists prospectively analyzed morphologic characteristics of tumors on breast MRI in consensus, blind to the clinico-pathologic information of patients. The longest diameter of tumor, shape, margin, internal enhancement pattern, and kinetic curve were analyzed by BI-RADS lexicon on early and late dynamic phase of DCE-MRI. Presence of peritumoral edema and number of prominent vessels around the tumor, which were known as imaging prognostic factors by previous studies, were assessed on T2WI and on maximal intensity projection (MIP) image, respectively. Fibroglandular tissue (FGT) pattern on T2WI, and background parenchymal enhancement (BPE) pattern on MIP images were also analyzed as non-tumor features in the contralateral breast, which was not involved by cancer.

Quantitative analysis of MR parameters. Apparent diffusion coefficient histogram. Post-processing was performed using in-house analysis software (EXPRESS; licensed by Jinwoo Hwang, Philips Healthcare Korea) to obtain ADC histogram of a defined tumor volume. Freehand type of region of interest (ROI) was manually drawn along the margin of the lesion for each image of ADC data. Then, a volume of interest (VOI) was defined as a stack of ROIs; and minimum, maximum, mean, 5th, 10th, 25th, 75th, 90th, 95th percentile ADC values, skewness and kurtosis of the pixels contained within the VOI were calculated (Fig. 3).

Perfusion parameter and texture analysis. The analysis for perfusion parameters was conducted in the same way as the previous study from our institution using a post-processing software (Olea Sphere, version 3.0, licensed by Olea Medical, La Ciotat, France). Texture analysis was also performed in Olea Sphere, with the same VOI drawn for perfusion parameter. We extracted first order features, gray level co-occurrence matrix (GLCM), and gray level run length matrix (GLRLM) from calculation on subtracted early dynamic phase T1WI, T2WI and ADC map. If the tumor was not clearly visualized on T2WI or ADC map, the VOI drawn on subtracted early dynamic phase T1WI was automatically applied at the similar location on T2WI or ADC map in the program and texture parameters were calculated (Fig. 4).

Pathologic analysis and immunohistochemistry. Tumor-stroma ratio. One HE-stained slide of representative tumor was analyzed on microscopic examination. As previously determined, cases with stroma proportion of < 50% were considered as stroma poor and cases with stroma proportion of ≥ 50% were regarded as stroma rich (17).

Angiogenesis assessment with CD34 and Notch1 immunohistochemical staining. Four µm-thick sections for immunohistochemical staining of CD34 and Notch1 were obtained from formalin-fixed paraffin embedded tissue. The used primary antibodies were anti-CD34 mouse monoclonal antibody (clone QBEnd 10, 1:100 dilution, Dako, Glostrup, Denmark) and anti-Notch1 rabbit monoclonal antibody (clone D1E11, 1:50 dilution, CST, Danvers, USA). The CD34 staining was performed using the DAKO Omnis automated immunohistochemistry
system (Dako). Tissue sections were deparaffinized with xylene, three times for 10 min, for Notch1 staining. Then, the sections were rehydrated using 100%, 95%, and 70% graded ethanol for 5 min, each after oven incubation at 60 °C for 1 h. Antigen retrieval was carried out in a pressure cooker (Electric Pressure Cooker CPC-600, Cuisinart, East Windsor, USA) for 20 min using 1× citrate buffer (pH 6.0). The endogenous peroxide activity was blocked by methanol-diluted 3% hydrogen peroxide for 15 min. Sections were incubated with the primary antibody for 1 h at room temperature (22–25 °C) in a humidified chamber. The immunoreaction signal was amplified and was revealed using the Polink-2 HRP DAB Broad-2 Detection system kit (GBI, Mukilteo, USA). Subsequently, these sections were counterstained with Harris's hematoxylin (YD Diagnostics, Y ongin, Korea).

We determined the MVD with CD34 immunostained tumor section. We counted the microvessels in the highest CD34 positive neovascularization areas (hot spots) of the tumor stroma. These were identified on the scan view in accordance with the method described by Weidner N (18). In the Notch1 immunostained slides, the highest Notch1 positive neovascularization areas (hot spots) were selected and counted Notch1 positive microvessels (Notch1 MVD). In the CD34 immunostained slides, the corresponding areas to Notch1 hot spots were selected and counted CD34 positive microvessels (CD34 MVD). The ratio of Notch1 MVD to CD34 MVD was defined as endothelial-Notch1 as previously described31. The EC Notch1 was classified into EC Notch1 low group or EC Notch1 high group based on the cutoff value. The cutoff value of EC Notch1 was set at the median expression value.

Statistical analysis. For analysis of characteristics of young age breast cancer, independent t test or Mann-Whitney test was used for continuous variables, and Chi-square or Fisher’s exact test was used for categorical variables. The correlation between MR parameters and pathologic factors was analyzed using Pearson or spearman correlation coefficient. The association between recurrence and baseline and clinical characteristics were performed to logistic regression analysis. All statistical analyses were used by SAS Version 9.4 (SAS Institute Inc, Cary, NC) and p value below 0.05 was considered statistically significant.
**Figure 4.** Texture analysis of invasive ductal carcinoma at 12 o’clock direction of right breast. Based on the VOI obtained from the perfusion parameters analysis (a), it was applied on subtracted early phase contrast enhanced T1WI (b), non-fat saturated T2WI (c), and ADC map (d). The color maps that do not match the tumor were manually modified using the original MR images of these sequences.

Received: 28 March 2021; Accepted: 14 September 2021
Published online: 12 October 2021

**References**

1. UK, C. R. Breast cancer incidence (invasive) statistics (2018).
2. Society, K. B. C. Breast Cancer Facts & Figures (2019) (2019).
3. Hortobagyi, G. N. et al. The global breast cancer burden: Variations in epidemiology and survival. *Clin. Breast Cancer* 6, 391–401. [https://doi.org/10.3816/cbc.2005.n.043](https://doi.org/10.3816/cbc.2005.n.043) (2005).
4. Leong, S. P. et al. Is breast cancer the same disease in Asian and Western countries? *World J. Surg.* 34, 2308–2324. [https://doi.org/10.1007/s00268-010-0683-1](https://doi.org/10.1007/s00268-010-0683-1) (2010).
5. Lee, H. B. & Han, W. Unique features of young age breast cancer and its management. *J. Breast Cancer* 17, 301–307. [https://doi.org/10.4048/jbc.2014.17.4.301](https://doi.org/10.4048/jbc.2014.17.4.301) (2014).
6. Yap, Y. S. et al. Insights into breast cancer in the east versus the west: A review. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.0620 (2019).

7. Lee, S. K. et al. Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer? Breast Cancer Res. Treat. 173, 189–199. https://doi.org/10.1007/s10549-018-4947-z (2019).

8. Kim, Y., Yoo, K. Y. & Goodman, M. T. Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing factors. Asian Pac. J. Cancer Prev. 16, 2857–2870. https://doi.org/10.7314/apjc.2015.16.7.2857 (2015).

9. Tripathy, D. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol. 19, 904–915. https://doi.org/10.1016/S1470-2045(18)30292-4 (2018).

10. Im, S. A. et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N. Engl. J. Med. 381, 307–316. https://doi.org/10.1056/NEJMoa1905765 (2019).

11. de Rocheforde, A. et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 341, 1039–1043. https://doi.org/10.1016/S0140-6736(93)92407-k (1993).

12. Han, W. et al. Young age: An independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4, 82. https://doi.org/10.1186/1471-2407-4-82 (2004).

13. Ko, E. S. et al. Apparent diffusion coefficient in estrogen receptor-positive invasive ductal breast carcinoma: Correlations with tumor-stroma ratio. Radiology 271, 30–37. https://doi.org/10.1148/radiol.13131073 (2014).

14. Li, L. et al. Parameters of dynamic contrast-enhanced MRI as imaging markers for angiogenesis and proliferation in human breast cancer. Med. Sci. Monit. 21, 376–382. https://doi.org/10.12659/MSM.892534 (2015).

15. Haldorsen, I. S. et al. Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. Br. J. Cancer. 110, 107–114. https://doi.org/10.1038/bjc.2013.694 (2014).

16. de Krijn, E. M. et al. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res. Treat. 125, 687–696. https://doi.org/10.1007/s10549-010-0855-6 (2011).

17. Uzzan, B., Nicolas, P., Cucherat, M. & Perret, G. Y. Microvessel density as a prognosis marker in women with breast cancer: A systematic review of the literature and meta-analysis. Cancer Res. 64, 2941–2955. https://doi.org/10.1158/0008-5472.can-03-1957 (2004).

18. Eugenio, D. S. et al. Breast cancer features in women under the age of 40 years. Rev. Assoc. Med. Bras. 1992(62), 755–761. https://doi.org/10.1590/1806-9282.62.08.755 (2016).

19. Durhan, G. et al. Imaging findings and clinicopathological correlation of breast cancer in women under 40 years old. Eur. J. Breast Health 15, 147–152. https://doi.org/10.1515/ebjh.2019.4606 (2019).

20. Lee, J., Kim, S. H. & Kang, B. J. Prognostic factors of disease recurrence in breast cancer using quantitative and qualitative magnetic resonance imaging (MRI) parameters. Sci. Rep. 10, 7598. https://doi.org/10.1038/s41598-020-64564-6 (2020).

21. Dogan, B. E. & Turnbull, L. W. Imaging of triple-negative breast cancer. Ann. Oncol. 23(Suppl 6), vi23–29. https://doi.org/10.1093/annonc/mds191 (2012).

22. Sung, J. S. et al. MR imaging features of triple-negative breast cancers. Breast J 19, 643–649. https://doi.org/10.1111/tbj.12183 (2013).

23. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938–1948. https://doi.org/10.1056/NEJMra1001389 (2010).

24. Newman, L. A., Reis-Filho, J. S., Morrow, M., Carey, L. A. & King, T. A. The 2014 society of surgical oncology Susan G. Komen for the cure symposium: Triple-negative breast cancer. Ann. Surg. Oncol. 22, 874–882. https://doi.org/10.1245/s10434-014-4279-0 (2015).

25. Kim, J. Y., Kim, J. H., Hwangbo, L., Kang, T. & Park, H. Diffusion-weighted imaging of invasive breast cancer: Relationship to distant metastasis-free survival. Radiology 291, 300–307. https://doi.org/10.1148/radiol.2019181706 (2019).

26. Ko, E. S. et al. Assessment of invasive breast cancer heterogeneity using whole-tumor magnetic resonance imaging texture analysis: Correlations with detailed pathological findings. Medicine (Baltimore) 95, e2453. https://doi.org/10.1097/MD.0000000000002453 (2016).

27. Panzeri, M. M. et al. Prediction of chemoresistance in women undergoing neo-adjuvant chemotherapy for locally advanced breast cancer: Volumetric analysis of first-order textural features extracted from multiparametric MRI. Contrast Media Mol. Imaging 2018, 8329041. https://doi.org/10.1155/2018/8329041 (2018).

28. Yoon, H. I., Kim, Y., Chung, J. & Kim, B. S. Predicting neo-adjuvant chemotherapy response and progression-free survival of locally advanced breast cancer using textural features of intratumoral heterogeneity on F-18 FDG PET/CT and diffusion-weighted MR imaging. Breast 35, 373–380. https://doi.org/10.1111/bbe.13032 (2019).

29. Monticciolo, D. L. et al. Breast cancer screening in women at higher-than-average risk: Recommendation from the ACR. J. Am. Coll. Radiol. 15, 408–414. https://doi.org/10.1016/j.jacr.2017.11.034 (2018).

30. Ahn, S. et al. The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biol. 33, 1573–1580. https://doi.org/10.1007/s13277-012-0411-6 (2012).

31. Kim, D. et al. Notch1 in tumor microvascular endothelial cells and tumoral miR-34a as prognostic markers in locally advanced triple-negative breast cancer. J. Breast Cancer 22, 562–574. https://doi.org/10.4048/jbc.2019.22.e56 (2019).

32. Choi, E. J., Choi, H., Choi, S. A. & Youk, J. H. Dynamic contrast-enhanced breast magnetic resonance imaging for the prediction of early and late recurrences in breast cancer. Medicine (Baltimore) 95, e5330. https://doi.org/10.1097/MD.0000000000005330 (2016).

33. Bae, M. S. et al. Pretreatment MR imaging features of triple-negative breast cancer: Association with response to neoadjuvant chemotherapy and recurrence-free survival. Radiology 281, 392–400. https://doi.org/10.1148/radiol.2016152331 (2016).

34. Kim, J. Y. et al. Enhancement parameters on dynamic contrast enhanced breast MRI: Do they correlate with prognostic factors and subtypes of breast cancer?. Magn. Reson. Imaging 33, 72–80. https://doi.org/10.1016/j.mri.2014.08.034 (2015).

Acknowledgements

This study was funded by Bayer Korea (Seoul, Korea). The statistical consultation was supported by Seoyeon Ok, researcher of Yonsei University Institute of Data Science, and Department of Biostatistics of the Catholic Research Coordinating Center, Catholic Medical Center, South Korea.

Author contributions

S.H.K. and J.L. are the guarantors of integrity of the entire study. S.H.K., J.L., B.J.K. and W.C.P. participated in patient enroll and followed the progress of enrolled patients. J.L., S.H.K., B.J.K. performed imaging data analysis. A.I.L. performed pathologic analysis and prepared Fig. 2 with its legend. J.W.H. developed and provided important programs for data analysis. J.L. and S.H.K. wrote the main manuscript text and all authors participated in editing and reviewing the manuscript.
Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-99600-6.

Correspondence and requests for materials should be addressed to S.H.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021